Madrigal Pharmaceuticals Q3 2025 Earnings Report

Madrigal Pharmaceuticals EPS Results

• Actual EPS: N/A
• Consensus EPS: -$2.01
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Madrigal Pharmaceuticals Revenue Results

• Actual Revenue: N/A
• Expected Revenue: $244.33 million
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Madrigal Pharmaceuticals Announcement Details

• Quarter: Q3 2025
• Date: 10/30/2025
• Time: Before Market Opens
• Conference Call Date: Thursday, October 30, 2025
• Conference Call Time: 8:00AM ET

Madrigal Pharmaceuticals (NASDAQ:MDGL) is a clinical-stage biopharmaceutical company focused on the development of innovative therapies for cardiovascular, metabolic and liver diseases. The company’s pipeline centers on novel, liver-directed agents designed to address significant unmet medical needs, with an emphasis on nonalcoholic steatohepatitis (NASH) and related metabolic disorders.

The lead product candidate, resmetirom (MGL-3196), is an orally administered, selective thyroid hormone receptor-β agonist in Phase 3 development for the treatment of NASH. Resmetirom has been engineered to target liver tissue in order to reduce hepatic fat accumulation, improve lipid profiles and attenuate fibrosis. The company’s clinical programs include global trials across North America, Europe and Latin America, reflecting its commitment to registering resmetirom in major markets.

In addition to its lead asset, Madrigal is advancing next-generation compounds for lipid disorders and other cardiovascular risk factors. The company engages in strategic collaborations to bolster its research capabilities and expand its therapeutic portfolio. Through a combination of in-house development and partnerships, Madrigal aims to bring multiple first-in-class or best-in-class therapies to patients.

Founded in 2013 and headquartered in Conshohocken, Pennsylvania, Madrigal is led by President and Chief Executive Officer Paul A. Friedman, M.D. The company’s management team comprises experienced biopharmaceutical executives and clinical researchers dedicated to transforming the treatment landscape for metabolic and liver diseases.